EP0427078A1 — Folinic acid-cyclodextrin inclusion compound
Assigned to Magis Farmaceutici SRL · Expires 1991-05-15 · 35y expired
What this patent protects
Complexes obtained by complexing folinic acid with α, β, γ, dimethyl-β or hydroxypropyl-β-cyclodextrin are described, having better activity in anemic syndromes due to folic acid deficiency than equivalent doses of the corresponding active principle. Furthermore the stabili…
USPTO Abstract
Complexes obtained by complexing folinic acid with α, β, γ, dimethyl-β or hydroxypropyl-β-cyclodextrin are described, having better activity in anemic syndromes due to folic acid deficiency than equivalent doses of the corresponding active principle. Furthermore the stability of said compounds in an acid environment renders them suitable to be administered by oral route.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.